Media Center

Vienna, Austria: – Recombinant proteins and plasmid DNA specialist CDMO enGenes Biotech is returning to the annual CHI Bioprocessing Summit with further insights on groundbreaking continuous production technologies for plasmid DNA (pDNA).

End-to-end bioprocessing specialist CDMO enGenes Biotech is deepening its relationship with North America’s biotech community through its new partnership with the Sweetgrass Bio consultancy.

We're excited to share a new collaborative white paper from enGenes Biotech and arcoris bio, tackling one of the biggest bottlenecks in multiplex immunofluorescence: inconsistent, hard-to-scale antibody labeling.

The growing demand for plasmid DNA (pDNA), driven by gene therapies and mRNA vaccines, continues to outpace manufacturing capacity. Current Escherichia coli (E.coli)-based production processes are limited by low strain productivity, complex downstream workflows, high impurity burden, and the sensitivity of alkaline lysis, resulting in scalability challenges and high cost of goods. This study evaluates the combined impact of strain selection (DH1 vs. eXcess™) and process desig

May 26, 2026 Matfors, Sweden / Vienna, Austria — May 26, 2026 NorthX Biologics and enGenes Biotech have partnered to deliver an integrated pathway for recombinant protein expression, process development, and GMP manufacturing in E. coli. The partnership addresses the disconnect between early-stage strain and expression system development and later-stage biologics manufacturing, which can extend development timelines by three to six months. The combined offering helps biopharm

By Alwin Schönberger - profil Nachrichtenmagazin More than five million people are bitten by venomous snakes every year, and at least 100,000 die. Researchers in Vienna have developed a new method to save lives. How the technology works, and why it could also combat other diseases. “There are seven steps until death,” says a proverb in East Africa. According to legend, after being bitten by a black mamba, a person can take exactly seven steps before collapsing lifeless to the

Vienna, Austria: – End-to-end bioprocessing specialist CDMO enGenes Biotech will bring details of its groundbreaking iCAP plasmid DNA continuous production platform to the upcoming annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Dublin. enGenes CEO Dr Jürgen Mairhofer will lead the company’s presence at the conference, which has become recognized as one of the world’s leading events in the field of Cell and Gene Therapy (CGT) Translation, attract

Vienna, Austria: – High-yield end-to-end bioprocessing specialist CDMO enGenes Biotech will be present at the upcoming BioProcess International (BPI) European conference in Vienna in late April 2026. enGenes Business Development Manager Ophelia Gevaert will represent enGenes at the conference to communicate the CDMO’s distinctive offers, technologies and capabilities in high end production of recombinant proteins, plasmid DNA, vaccines, antibodies, and peptides. Proprietary

Vienna, Austria – enGenes Biotech will showcase its industry-leading automated and continuous plasmid DNA (pDNA) production capabilities at the annual BioProcess Summit Europe 2026 in Barcelona. The enGenes team, led by CEO Dr. Juergen Mairhofer, will contribute to the Summit’s Intensified and Continuous Processing stream with a presentation demonstrating the impact of its iCAP platform on next-generation plasmid DNA manufacturing. iCAP: Unlocking continuous bioprocessing O

Introduction Recombinant protein production is essential for pharmaceutical development, diagnostics, and industrial applications. However, achieving high yields of soluble, active proteins – especially for difficult-to-express targets – remains a significant challenge. This article explores advanced solutions for cost-effective protein production, from overcoming expression limitations in standard E. coli strains to implementing extracellular secretion strategies that simpli